Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2002

View Archived Issues

Improved pharmacokinetic profile reported for new nasal nicotine formulation

Improvement of natural learning impairment after administration of H3 receptor antagonists in rats

Daily Z-335 is safe and effectively blocks thromboxane A2 receptors

DAC:Opioid returns mixed results

Crucell licenses PER.C6 cell line for use in GenVec's BioBypass

Adolor enters opioid antagonist license agreement with Lilly

ARC enters research agreement with McGill University for antisense oligonucleotide therapeutics

ProdiGene and NIAID to begin phase I trial of oral traveler's diarrhea vaccine

Phase I solid tumor trial initiated for KSP inhibitor

Salicylate protects against the ototoxic and nephrotoxic side effects of cisplatin in rats

Iressa NSCLC trial results show no improvement in combined treatment with standard chemotherapy

Potent, selective and orally bioavailable FTase inhibitor presented by Abbott

Ras-MAPK signaling cascade inhibitors prepared and tested at Wyeth

Abbott reports novel HDAC inhibitors at the ACS meeting

Merck & Co. discloses novel HIV protease inhibitors

Nocathiacin I derivatives with in vivo antibacterial activity presented at ACS

New PPARalpha/delta receptor agonists covered by GSK patent

Merck claims alphavbeta3 and/or alphavbeta6 antagonists for cardiovascular and other disorders

Novel prostaglandin EP4 antagonists and their use in neuropathic pain